Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer.

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Genetics

Background:

• DNA damage repair pathways are crucial for cellular integrity, and their dysregulation is linked to cancer.
• Synthetic lethality (SL) is a therapeutic strategy exploiting gene function loss for selective cancer cell death.
• Cisplatin (CPT) is a chemotherapy agent effective against many cancers but faces resistance and toxicity in prostate cancer (PCa).

Purpose of the Study:

• To investigate the therapeutic potential of targeting TLK1 kinase in androgen-insensitive prostate cancer.
• To explore the combination of CPT with a TLK1 inhibitor (J54) to overcome CPT resistance.
• To elucidate the role of TLK1 in homologous recombination repair (HRR) and its impact on CPT sensitivity.

Main Methods:

• Assessed TLK1 upregulation in androgen-insensitive PCa cells.
• Investigated the effect of combining CPT with TLK1 inhibitor J54.
• Analyzed the impact of TLK1 inhibition on HRR protein phosphorylation (RAD54L, RAD54B).
• Evaluated synthetic lethality in PCa cells treated with CPT and J54.

Main Results:

• TLK1 is upregulated in androgen-insensitive PCa cells.
• The combination of CPT and J54 demonstrated synthetic lethality in PCa cells.
• TLK1 inhibition impaired HRR, crucial for repairing CPT-induced DNA damage.
• Targeting TLK1 increased PCa cell sensitivity to CPT.

Conclusions:

• TLK1 inhibition enhances CPT efficacy in prostate cancer by disrupting DNA repair.
• The combination of CPT and J54 presents a promising synthetic lethality strategy for androgen-insensitive PCa.
• Targeting TLK1 offers a potential approach to overcome CPT resistance in prostate cancer and other malignancies.